Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
保存先:
主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
フォーマット: | Revisão |
言語: | 英語 |
出版事項: |
2023
|
オンライン・アクセス: | https://doi.org/10.1002/art.42538 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|